Eli Lilly Launches Mounjaro Kwikpen in India, Intensifying Weight-Loss Drug Market Rivalry
Eli Lilly has introduced its easy-to-use Mounjaro Kwikpen in India, priced at ₹14,000 (about $160) for the starting 2.5 mg dose, aiming to strengthen its foothold in the booming weight-loss drug segment. The launch follows regulatory approval in June, just two days after rival Novo Nordisk rolled out its Wegovy pen device in multiple dose strengths. Mounjaro will be available in six strengths ranging from 2.5 mg to 15 mg, with monthly prices rising from ₹14,000 to ₹27,500 depending on dosage.
The competitive pricing pits Mounjaro against Wegovy, which starts at ₹17,345 for its smallest doses and goes up to ₹26,015 for its highest strengths. Analysts say Lilly’s strategy could lure more patients, noting that the highest doses of Mounjaro are slightly cheaper than Wegovy’s top-tier offerings. Both drugs, part of the GLP-1 receptor agonist class, help control blood sugar and promote weight loss by slowing digestion and increasing satiety.
Lilly began selling Mounjaro in vial form for diabetes and obesity treatment in March, and both its and Novo’s drugs have seen soaring demand, with July sales doubling from the previous month. As India’s market for advanced weight-loss and diabetes solutions grows rapidly, the entry of the Kwikpen device is set to escalate the battle for market share in this lucrative segment.
Pic Courtesy: google/ images are subject to copyright
